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Purpose: This study was conducted to investigate whether retinoic acids (RAs) had any effect 
on apoptosis during the development of diabetic retinopathy.
Methods: To investigate whether RAs had any effect on apoptosis during the development 
of diabetic retinopathy, we housed 32 C57BL/6 male mice and induced diabetes in 24 by intra 
peritoneal injections of streptozotocin (STZ; Sigma, St Louis, MO) and treated 16 of the diabetic 
mice with the RAs, all-trans-retinoic acid (ATRA) (seven mice) and 4-[(5,6,7,8-tetrahydro-
5,5,8,8-tetramethyl-2-naphthalenyl)carboxamido] benzoic acid (Am580) (nine mice). The 
other eight mice were used as diabetic controls. We then measured apoptosis in the retina by 
TdT-dUTP terminal nick-end labeling assay.
Results: RAs inhibited the apoptosis of retinal cells in diabetic retinopathy. Many apoptotic 
cells were observed in retinas of the eight diabetic control mice (mean value and SD: 37.8 ± 6.9), 
whereas when diabetic mice were treated with RAs, the number of apoptotic cells signiﬁ  cantly 
decreased (mean value and SD: 9.9 ± 6.4 for the seven ATRA-treated diabetic mice and 9.8 ± 
5.9 for the nine Am580-treated diabetic mice) (p   0.05).
Conclusion: Treatment with RAs decreases apoptosis during the development of diabetic 
retinopathy.
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Introduction
In Japan, more than 12 million people are believed to suffer from diabetes (Kawamori 
2002). The most common complication of diabetes is diabetic retinopathy, which is the 
leading cause of legal blindness among working-age adults in Japan. The functional 
components of diabetic retinopathy are vascular permeability and neural cell death. 
Recent studies have shown that most of the neural cell death in retinas associated with 
diabetic retinopathy is due to apoptosis (Barber et al 1998; Tezel et al 1999).
Some glial cells are well known to maintain survival of neural cells by production 
of various cytokines. Recently we reported that retinoic acid receptor stimulants such 
as all-trans-retinoic acid (ATRA) and 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-
naphthalenyl)carboxamido] benzoic acid (Am580) improve diabetic retinopathy via 
changes of cytokine production in glial cells (Thang et al 2000; Nishikiori et al 2007a). 
In this study, we investigated whether RAs had any effect on apoptosis during the 
development of diabetic retinopathy.
Material and methods
To determine whether RAs had any effect on apoptosis during the development of dia-
betic retinopathy, 32 C57BL/6 male mice (5 weeks old, CLEA JAPAN, Tokyo, Japan) 
were housed and diabetes was induced in twenty-four mice by intra peritoneal (i.p.) 
injection of 40 mg/kg streptozotocin (STZ; Sigma, St Louis, MO) dissolved in 0.01M Clinical Ophthalmology 2008:2(1) 234
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trisodium citrate buffer (pH 4.5) for 5 consecutive days. The 
cut-off levels in mice used to diagnose diabetes were more 
than 200 mg/dl in blood sugar measured using Gluco-card 
(ARKRAY, Kyoto, Japan) and positive urinal sugar measured 
using Rub-stick (Bayer, Leverkusen, Germany). Six weeks 
after the veriﬁ  cation of diabetes, when the blood–retinal 
barrier breakdown was progressing as previously described 
(Nishikiori et al 2007a), mice were treated with 1.0 mg/kg 
ATRA every day (seven mice, 14 eyes) or 3.75 mg/kg Am580 
every other day (nine mice, 18 eyes) for 1 week (Nishikiori 
et al 2007a, 2007b). Control mice (eight mice, 16 eyes) were 
i.p. injected with a solvent alone (250 μl of DMSO; Sigma). 
After the mice were sacriﬁ  ced by dislocating the cervical 
vertebrae, enucleated mouse eyeballs were ﬁ  xed in 1% 
paraformaldehyde/phosphate-buffered saline overnight. 
After the eyeballs were sliced in horizontal sections and ﬂ  at-
mounted onto a slide, TdT-dUTP terminal nick-end labeling 
(TUNEL) was performed using the In Situ Cell Death Detec-
tion Kit, Fluorescein (Roche, Basel, Switzerland). Using a 
laser-scanning confocal microscope (MRC 1024; Bio-Rad, 
Hercules, CA), the numbers of apoptotic cells in the retinas 
of all 64 eyes of the 32 mice were counted in 3∼4 views of 
the retinas approximately 100 μm from the center of the optic 
nerve disk in each eye at the same magniﬁ  cation (×20) and 
averaged. All animal experiments followed the speciﬁ  ca-
tions of the Guidelines for Animal Experiments of Sapporo 
Medical University School of Medicine. All values are 
expressed as mean and SD. Data were statistically analyzed 
with the Fisher test for comparison of four groups. The levels 
of statistical signiﬁ  cance was set at p   0.05.
Results
RAs inhibited the apoptosis during the development of 
diabetic retinopathy. To demonstrate this, we treated diabetic 
mice with ATRA or Am580 and measured apoptosis in the ret-
ina by TUNEL assay. Many apoptotic cells were observed in 
the retinas of the eight control diabetic mice (cell counts; max 
60, minimum 30, mean value and SD: 37.8 ± 6.9), whereas 
when 16 diabetic mice were treated with ATRA or Am580, 
the number of apoptotic cells markedly decreased (cell counts; 
max 23, minimum 5, mean value and SD: 9.9 ± 6.4 in seven 
ATRA-treated diabetic mice and max 20, minimum 5, mean 
value and SD: 9.8 ± 5.9 in nine Am580-treated diabetic mice), 
and the level was suppressed nearly to the control level (cell 
counts; max 8, minimum 0, mean value and SD: 6.3 ± 2.6 in 
eight control mice) (Figures 1A and B).
Discussion
In this study, we demonstrated a marked decrease of apop-
tosis during the development of diabetic retinopathy after 
treatment with RAs, though the mechanisms by which 
this occurred have not yet been clariﬁ  ed. RA, an essential 
signaling molecule throughout life (Mangelsdorf et al 
1994; Kastner et al 1995), could play an important role in 
the induction of glial cell line-derived neurotrophic factor 
(GDNF) in glial cells (Thang et al 2000; Nishikiori et al 
2007a). GDNF is a neurotrophic and differentiation factor 
in the retina (Koeberle et al 1998; Thang et al 2000; McGee 
Sanftner et al 2001; Politi et al 2001; Wu et al 2004) as well 
as the central nervous system (Lin et al 1993; Henderson 
et al 1994). Therefore one possible explanation is that RAs 
Figure 1 RAs inhibited the apoptosis during the development of diabetic retinopathy. A and B, Apoptosis of retinal cells in retina. (A, apoptotic cell counts, TdT-dUTP 
terminal nick-end labeling assay. B, laser-scanning confocal analysis.)
Abbreviations: Ctrl, control mice;   ATRA, all-trans-retinoic acid (ATRA)-treated diabetic mice; Am580, Am580-treated diabetic mice; DM, diabetic mice.
Notes: **p   0.01 Scale bars: 25 μm. The choroid (C), retinal pigment epithelium (RPE), outer nuclear layer (ONL), outer plexiform layer (OPL), inner nuclear layer (INL), 
inner plexiform layer (IPL), and the ganglion cell layer (GCL) are labeled in the micrograph.
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protect retinal cells in diabetic retinopathy by inducing GDNF 
production in glial cells in the retina (Nishikiori et al 2007a, 
2007b). GDNF affects a wide variety of signaling pathways 
(Jing et al 1996; Treanor et al 1996; Airaksinen et al 2002) 
and there are many signaling pathways of apoptosis in retinal 
cells (Altucci et al 2001). Judging from the distribution of 
apoptosis in the retina, however, we cannot say anything 
about which cell type preferentially fell into apoptosis or 
which cell type was prevented from doing so by RAs, though 
several reports suggest that apoptosis in the retina preferen-
tially occurs in retinal ganglion cells with photoreceptors 
(Koeberle et al 1998; Wu et al 2004).
Considering the observations of this study, we would 
like to make two proposals. One is that RAs are promising 
drugs for diabetic ophthalmic disease because they have 
anti-cataractogenic effects for diabetic cataracts (Nishikiori 
et al 2007b), blood–retinal barrier-protective effects for vas-
cular integrity (Miyajima et al 2005; Nishikiori et al 2007a), 
and neuroprotective effects against apoptosis in diabetic 
retinopathy. The other is that glial cells in the retina can be 
a new target for treating the retinopathy. Although we i.p. 
injected RAs, another drug delivery assay such as intravitreal 
injections will be examined to make RAs more effective 
on glial cells. Future work along the lines of our proposals 
might provide a fundamental understanding of the treatment 
effects of RAs and the treatment targets of glial cells in the 
development of diabetic ophthalmic diseases. RAs might 
increase neurotrophic cytokines such as GDNF in glial cells, 
contributing to decreased apoptosis during the development 
of diabetic retinopathy. Hopefully, this study will help to 
improve the outcomes of patients with diabetes.
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